Compare SFIX & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFIX | ASMB |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.4M | 512.1M |
| IPO Year | 2017 | 2010 |
| Metric | SFIX | ASMB |
|---|---|---|
| Price | $3.59 | $32.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $4.50 | ★ $44.20 |
| AVG Volume (30 Days) | ★ 1.4M | 158.7K |
| Earning Date | 06-09-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 79.44 | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,226,505,000.00 | N/A |
| Revenue This Year | $8.04 | N/A |
| Revenue Next Year | $3.73 | $638.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.52 | N/A |
| 52 Week Low | $2.95 | $20.23 |
| 52 Week High | $5.92 | $39.71 |
| Indicator | SFIX | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 41.64 | 75.27 |
| Support Level | $3.43 | $31.51 |
| Resistance Level | $3.64 | $39.17 |
| Average True Range (ATR) | 0.20 | 1.31 |
| MACD | -0.06 | 0.59 |
| Stochastic Oscillator | 7.65 | 98.38 |
Stitch Fix Inc offers personal style services for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandise with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types, and price points including Women's, Petite, Maternity, Men's, and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry, and handbags and sells merchandise across various ranges of price points.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.